Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,795 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Genetic Change Clear all

Conditions: Metastatic Cancer
Interventions: Palliative radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cystic Fibrosis
Interventions: Elexacaftor-tezacaftor-ivacaftor exposure; Drug
Lead sponsor: Jennifer Taylor-Cousar; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: dabrafenib, pazopanib hydrochloride, Correlative studies; Drug · Other
Lead sponsor: Manisha Shah; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Columbus, Ohio • Houston, Texas

Conditions: Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Interventions: avutometinib (VS-6766), avutometinib (VS-6766) and defactinib; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Scottsdale, Arizona • Santa Barbara, California • New Haven, Connecticut + 23 more

Conditions: Lung Cancer, Driver Mutation
Interventions: Low Dose CT Scan; Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Interventions: Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib; Drug · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Duarte, California • Columbus, Ohio • Houston, Texas

Conditions: Cystic Fibrosis, Advanced Lung Disease
Interventions: Lumacaftor, Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more

Conditions: Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
Interventions: Observational; Other
Lead sponsor: Escape Bio, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Culver City, California

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic or Unresectable Cutaneous Melanoma
Interventions: MEK162, Dacarbazine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 77
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Altamonte Springs, Florida + 46 more

Conditions: Neoplasms
Interventions: Vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 12
States / cities: Rogers, Arkansas • Los Angeles, California • Torrance, California + 8 more

Conditions: Major Depressive Disorder
Interventions: Deplin®; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 554 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Greensboro, North Carolina • Nashville, Tennessee

Conditions: Dentatorubral-Pallidoluysian Atrophy
Interventions: nL-ATN1-002; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 29 Years to 29 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions: PARP Inhibitor BGB-290, Temozolomide (TMZ); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 39 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Lung Cancer, Breast Cancer
Interventions: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 14
States / cities: Birmingham, Alabama • Miami, Florida • Iowa City, Iowa + 9 more

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
Interventions: Capmatinib, Trametinib; Drug
Lead sponsor: Collin Blakely; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Choroideremia
Interventions: Vitamin A palmitate; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 15 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pharmacodynamic Study, Positron Emission Tomography, Telaglenastat Hydrochloride; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 31
States / cities: Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 23 more

Conditions: Adenocarcinoma of Lung, Stage IV
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cancer, Cancer Metastatic, BRAF V600E, MEK1 Gene Mutation, MEK2 Gene Mutation, ERK Mutation, RAF1 Gene Mutation
Interventions: Abemaciclib, LY3214996; Drug
Lead sponsor: Anita Turk; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Binimetinib, Encorafenib; Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more

Search by objective public record fields.

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Impact of Triple Combination CFTR Therapy on Sinus Disease.

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Lung Cancer Mutation Consortium Protocol

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation